ライフサイエンスコーパス: agent

1 cin (7 + 3 or equivalent) or hypomethylation agent).

2 t-suppressed T2-weighted images (no contrast agent).

3 ource of free radicals and a dehydrogenating agent.

4 f a linear vinyl ether as the chain transfer agent.

5 y varying the ratio of olefin/chain-transfer agent.

6 -targeted peptide conjugate as a theranostic agent.

7 o the bovine spongiform encephalopathy (BSE) agent.

8 ted with developing this type of therapeutic agent.

9 to master its potential use as a therapeutic agent.

10 o cisplatin, a DNA-damaging chemotherapeutic agent.

11 -vinylpyrrolidone) (PVP) the shape-directing agent.

12 y of alkali metal salts as a charge-reducing agent.

13 ing the microbiome to develop an efficacious agent.

14 sence of a catalyst to activate the reducing agent.

15 that CC extract is a potential antibacterial agent.

16 ing capability of the current antiangiogenic agents.

17 er sensitivity or resistance to DNA-damaging agents.

18 uated in combination with other antilymphoma agents.

19 ionizing radiation, among other DNA damaging agents.

20 et for the development of new anti-infective agents.

21 c genes and putative causative environmental agents.

22 disease therapy using available therapeutic agents.

23 y reactivated by different latency reversing agents.

24 ity for polymyxins compared with alternative agents.

25 DPP-4) which limits their use as therapeutic agents.

26 pid-lowering mediations, and cardiometabolic agents.

27 nd modulate extracellular spaces via osmotic agents.

28 of diltiazem and tiazesim, both therapeutic agents.

29 f repeated administration of pharmacological agents.

30 tionships (SARs) for prospective therapeutic agents.

31 ve had previous therapy with hypomethylating agents.

32 use of EP2 antagonists as anti-inflammatory agents.

33 VOC biomarkers from two potential biowarfare agents.

34 m heart failure outcomes observed with these agents.

35 poration, even in the presence of templating agents.

36 ty ultrasound and microbubbles or cavitation agents.

37 ncer cells with increased levels of reducing agents.

38 roader utility for PARP-targeted therapeutic agents.

39 noglobulin replacement and immunosuppressive agents.

40 ove the efficacy of conventional therapeutic agents.

41 d alternative methods of detecting biothreat agents.

42 xposure to various gadolinium-based contrast agents.

43 WSPM and multiple prototypical ERS-inducing agents.

44 mplex surface chemistries acting as blocking agents.

45 her combinations of nanocrystals and capping agents.

46 e or from the extrinsic administration of IS agents.

47 ternal cognitive processes across individual agents.

48 of countless natural stimuli and therapeutic agents.

49 mmatory therapies, and novel immunometabolic agents.

50 3' U and G nucleotides become gene-silencing agents.

51 with Gd(III) complexes as T(1) MRI contrast agents.

52 targets for the design of novel antimalarial agents.

53 es, and are considered potential therapeutic agents.

54 with anti-vascular endothelial growth factor agents.

55 de compatible with several external trapping agents.

56 are widely used as fertilizer and oxidizing agents.

57 ecules, nanoparticles, and other therapeutic agents.

58 in anticancer therapies involving DNA damage agents.

59 n mice treated with the endoradiotherapeutic agent (153)Sm-EDTMP.

60 nt cancer positron emission tomography (PET) agent [(18)F]5-fluorouracil ([(18)F]FU).

61 ethotrexate); (2) anti-tumor necrosis factor agents; (3) combination therapy; and (4) no treatment wi

62 were largely due to a lack of MMP-selective agents; accordingly, it has become important to identify

63 Here, we show that genotoxic agent-activated Wnt/beta-catenin signaling is independen

64 tibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B

65 ails the current landscape of antithrombotic agents, addresses challenges with preventing thromboembo

66 application as refrigerants, foam expansion agents, aerosol propellants, and precision solvents.

67 be used as promising eco-friendly biological agents against C. capitata.

68 e of copper ions, are effective bactericidal agents against MRSA.

69 (VSV)-based oncolytic viruses are promising agents against pancreatic ductal adenocarcinoma (PDAC).

70 as potential therapeutic and/or prophylactic agents against SARS-CoV-2.

71 ontrolled trials including the use of either agent alone are needed to confirm these results.

72 nce encountered during treatment with single agent alone.

73 activation, however, may be detrimental, and agents amenable to tissue targeting for therapeutic appl

74 (ethylene glycol) is considered the reducing agent and poly(N-vinylpyrrolidone) (PVP) the shape-direc

75 unomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in

76 rful way to control the release of bioactive agents and imaging probes.

77 ch as anti-hypertensive drugs, anti-platelet agents and statins) seem to have little or no effect on

78 in particular, has leveraged advances in MI agents and technology to improve the accuracy of tumor d

79 th populations is the need for new antiviral agents and the necessity for combination therapies as ha

80 ges and limitations of current T(1) contrast agents and the potential of IONPs to serve as safe and i

81 oil matrix using sonication and a dispersing agent, and (iii) separating the dissolved and nanopartic

82 patients, those receiving immunosuppressive agents, and especially those receiving combination thera

83 e food systems, reduction in climate forcing agents, and reduction in wildfires.

84 p for designing fluorophores, photoswitching agents, and triplet excited state quenchers for single-m

85 n and inhibition by covalent and noncovalent agents; and finally, the potential value of NAAA-targeti

86 The objective response rate (ORR) for single-agent anti-programmed death receptor 1 (anti-PD-1) thera

87 -trans-RA or previous RA metabolism blocking agents, appears to protect epidermal barrier integrity.

88 The agents are all able to reciprocally transfer Bitcoins us

89 , the fundamental principles of MRI contrast agents are discussed, and the current status of MRI cont

90 Anti-VEGF agents are efficient treatment to maintain visual acuity

91 ctive clinical trials involving (177)Lu-PSMA agents are under way that will likely pave the way for F

92 The antimalarial agents artemisinins inhibit cytomegalovirus (CMV) in vit

93 In this Perspective, we define these agents as 'proteomimetics' and discuss the recent advanc

94 nstrated that SimCells can be used as a safe agent (as they cannot replicate) for bacterial therapy.

95 ur mathematical analysis with the results of agent-based computation and, making use of approximate B

96 Here, we present results of a stochastic agent-based microsimulation model of the COVID-19 epidem

97 A hybrid mechanical and agent-based model (Mech-ABM), simulating mechanotransduc

98 d sequence, and a multiecho dynamic contrast agent-based sequence.

99 re the differential equation version with an agent-based version of the model run on the empirical ne

100 we interpret behavioral data by assuming an agent behaves rationally-that is, it takes actions that

101 tics is that patients tend to tolerate these agents better than chemotherapy.

102 ompounds, with a potential as anti-Alzheimer agents beyond that of the original lead CR-6.

103 by improving the conspicuity of the contrast agent, but more data are needed.

104 We searched for new agents by high-throughput screening of selected targeted

105 When this is not the case, the agent can still exploit the task solutions by using them

106 These new agents can be classified into different groups, mainly a

107 ansmitted obligate intracellular rickettsial agent, causes human monocytic ehrlichiosis.

108 ophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regi

109 The chemotherapeutic agent cisplatin is renowned for its ototoxic effects.

110 lood pressure lowering with antihypertensive agents compared with control was significantly associate

111 and (4) no treatment with immunosuppressive agents (control group).

112 ee drugs, non-targeted liposomes, and single-agent controls and reduces severe BTZ-associated side ef

113 may include discontinuation of the specific agent, corticosteroids, and other immune suppressing age

114 the combination of cytotoxic and cytostatic agents could represent an important modality in those tu

115 ion with the catalyst, protic chain transfer agents (CTAs) initiate polymerization and facilitate rap

116 However, the agents currently used to delineate those lesions (topica

117 s with diabetes; conventional renoprotective agents did not therapeutically target this elevation.

118 vity to the DNA damage-inducing chemotherapy agent doxorubicin.

119 affected independent from the pharmacologic agent, drug concentration, and direction of change in th

120 f action: VEGF inhibitors or anti-angiogenic agents, EGFR inhibitors, mTOR inhibitors, CTLA-4 inhibit

121 n This study indicated that dynamic contrast agent-enhanced perfusion MRI parameter, fractional plasm

122 dexamethasone (DEX) and the chemotherapeutic agent etoposide.

123 Single-agent EV was generally well tolerated and provided clini

124 es that can be protective against infectious agents exhibiting the same carbohydrate modification on

125 s utilizing iron pentacarbonyl as a reducing agent followed by subsequent oxidation leads to a great

126 ctrode (SPCE) using chitosan as cross-linked agent for 5-HT sensing studies; conducted through cyclic

127 be considered as a promising boron delivery agent for BNCT.

128 nolin-3-yl)methanimine oxide (17) is a novel agent for cerebral ischemia therapy as it is able to sca

129 -associated herpesvirus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common maligna

130 as been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-

131 terial may be developed as an anti-bacterial agent for prolonging the shelf life of tuna fish.

132 amino acid, offers new hope as a therapeutic agent for refractory TLE.

133 SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19

134 s, may represent a new class of psychotropic agent for the treatment of psychosis in schizophrenia.

135 xposed to standard-of-care chemotherapeutics agents for 2 weeks, attesting the ability of the platfor

136 ve been widely described as potent cytotoxic agents for cancer cells.

137 consideration as a new class of therapeutic agents for controlling cancer metastasis.

138 r the predictive values of molecular imaging agents for endocrine therapy response.

139 um-based chelates are a mainstay of contrast agents for magnetic resonance imaging (MRI) in the clini

140 g leads to be developed as novel therapeutic agents for SCD.

141 orticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse

142 the potential to be developed as therapeutic agents for the treatment and control of Ebola virus infe

143 using metal complexes as ER stress-inducing agents for the treatment of cancer is provided, along wi

144 n, and Zn turns Li(2) S into a prelithiation agent, forming metal sulfides rather than S(8) after the

145 ation of a uniquely reactive Bi(V) arylating agent from a bench-stable Bi(III) precursor via telescop

146 000 experimental records for anti-retroviral agents from ChEMBL database were extracted for creating

147 ogy as a group III gadolinium-based contrast agent (GBCA), which indicates that there are limited dat

148 te the wide use of gadolinium-based contrast agents (GBCAs) for enhanced MRI, their neurochemical and

149 and bovine serum albumin (BSA) as a blocking agent generated a moderate sensitivity of 0.0164 OD.mL/n

150 that the capacity to compute models of other agents has deep roots in the strategic social behavior o

151 such as chemotherapy and novel anti-androgen agents has further hampered progress.

152 Biologic agents have become a core component of therapeutic strat

153 Many microbial agents have been implicated as contributors to cancer ge

154 Although several immunotherapeutic agents have been utilized in the clinic for cancer treat

155 However, to date, pharmacological agents have failed to achieve significant target engagem

156 Studies in developing IONPs as T(1) contrast agents have generated promising results, but the complex

157 Photodynamic agents have the potential to combine both fluorescence f

158 In the absence of anti-EBV agents, however, therapeutic options for EBV-related dis

159 en that includes an additional antimicrobial agent (ie, CRO 250 mg, intramuscular single dose).

160 Single-agent immune modulators have thus far proven clinically

161 Gadolinium-based contrast agents improved diagnostic performance in detection of r

162 phylococci are a highly prominent infectious agent in peritonitis, and suggest caution against antico

163 to determine that rigosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells b

164 of nucleobases are accessible to alkylating agents in canonical dsDNA and that Hoogsteen base pairs

165 oduction of sulfated proteins as therapeutic agents in mammalian systems.

166 y of anti-vascular endothelial growth factor agents in the treatment of DME as well as the difference

167 We tested the effects of identified agents in zebrafish with disruption of ttc7a, which deve

168 pecific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prostate

169 We have previously developed agents incorporating spiropyran derivatives as the sensi

170 Introduction of pore partition agents into hexagonal channels of MIL-88 type (acs topol

171 This agent is protein S, which is both an anticoagulant in th

172 n one cancer-related pathway by multi-target agents is an emerging approach in modern anticancer drug

173 ssed, and the current status of MRI contrast agents is reviewed with a focus on the advantages and li

174 nolate mofetil (MMF) is an immunosuppressive agent (IS) which is widely prescribed in neuromyelitis o

175 Finally, we show that active inference agents learn models that are parsimonious, tailored to a

176 etable machine learning for quantifying both agent-level features and global pattern attributes on a

177 this approach does not depend on the use of agents like luciferin, which can cause variability due t

178 he radiopaque drug-carrier and micro-embolic agent Lipiodol, which has been previously established as

179 his approach, we have used the antihistamine agent loratadine (1).

180 in value-based decision-making tasks is that agents make decisions based on the feature dimension tha

181 quently, this pH-activatable optical imaging agent may be clinically beneficial in differentiating pr

182 clonal antibodies against infectious disease agents may be debatable, the functional characterization

183 been tacitly believed that the use of these agents may facilitate viral disease; thus, they should n

184 , but available evidence suggests that these agents may have therapeutic effects in specific psychiat

185 Adverse events from these agents might affect the ability of patients to tolerate

186 List prices of noninsulin antidiabetic agents (n = 10) increased by 165%, and net prices decrea

187 vide a balance of accessibility to reductive agents necessary to ensure stability in transit, but rap

188 potent greenhouse gas and an ozone-depleting agent, nitrous oxide (N(2)O) plays a critical role in th

189 anti-programmed cell death protein 1 (PD-1) agents (nivolumab or pembrolizumab) was conducted to ass

190 Upon exposure of human cells to DNA-damaging agents, NUCKS1 controls the resolution of RAD54 foci.

191 o 80% of the population and is the causative agent of a fatal demyelinating disease of the central ne

192 us pleuropneumoniae (App) is the etiological agent of acute porcine pneumonia and responsible for sev

193 Yersinia pestis is the causative agent of bubonic, pneumonic, and septicemic plague.

194 ory to infection by Dirofilaria immitis, the agent of canine heartworm disease, mounts a stronger imm

195 n parasite Trypanosoma cruzi, the aetiologic agent of Chagas disease.

196 me coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), uses the v

197 coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, has been found closely related to the

198 coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, is considered a zoonotic pathogen mai

199 Lightning is a major agent of disturbance, but its ecological effects in the

200 Phytophthora capsici Leonian, the causal agent of foliar blight, root rot, fruit rot and crown ro

201 ae was thought to be the exclusive causative agent of leprosy until Mycobacterium lepromatosis was id

202 an intracellular bacterium and the causative agent of melioidosis, a severe disease in tropical regio

203 o challenge with ectromelia virus (ECTV; the agent of mousepox) and that natural killer (NK) cells in

204 propose that social resistance can act as an agent of selection on key life-history strategies and pr

205 oronavirus 2 (SARS-CoV-2) is the etiological agent of the currently uncontrolled coronavirus disease

206 discover lysis inhibition in the etiological agent of the diarrheal disease cholera, Vibrio cholerae,

207 mpen the spread of SARS-CoV-2, the causative agent of the diseases, through restrictive interventions

208 ogen Francisella tularensis is the etiologic agent of tularemia, a potentially fatal disease if untre

209 al pathogen Sclerotinia sclerotiorum, causal agent of white mold diseases on hundreds of plant specie

210 ng depolarizations (SDs) and seizures, known agents of clinical worsening after TBI.

211 eved by establishing interdependencies among agents of different kinds.

212 es of the protozoan Leishmania are causative agents of human leishmaniasis, a disease that results in

213 tains a plethora of biomarkers and causative agents of various diseases, some of which are endogenous

214 However, the efficacy of these agents often decreases over time, which leads to treatme

215 ocal or systemic immunity against infectious agents or cancer.

216 by either combining different HER2-targeted agents or extending the duration of HER2-targeted therap

217 The 2 agents otherwise demonstrated no difference in positive

218 ) than the time required for chemomechanical agents (p = 0.0001).

219 oated balloons delivering the antirestenotic agent paclitaxel may improve outcomes.

220 his heterogeneous redistribution of contrast agent paralleled the gradients and regional variations i

221 esign concepts for more efficient polarizing agents (PAs).

222 anotubes, which are wrapped by encapsulation agent (phospholipid-polyethylene glycol), is demonstrate

223 The lead agent protects neurons from death in vivo.

224 While antiviral agents provide effective prophylaxis, there are several

225 y controlled chemoattractant and therapeutic agent release.

226 sRCCs, although a proven effective systemic agent remains elusive.

227 ding cause of death from a single infectious agent, requiring at least 6 months of multidrug treatmen

228 Bats are also major hosts for biological agents responsible for zoonoses, such as coronaviruses (

229 s release of the chemoattractant and killing agents result in long-range chemotactic attraction, trap

230 le for factor XII and XI as targets for such agents, reviews the data on the factor XII- and factor X

231 dults' reaction times reliably reflected the agent's beliefs only when the agent was free to act on t

232 The origin and emergence of its causal agent, SARS-CoV-2, in the human population remains myste

233 Benign selection agents serve as alternatives to antibiotics, which are c

234 excluded if they focused solely on contrast agents, served as commentaries/overviews on NIRAF or wer

235 The causative agent, severe acute respiratory syndrome coronavirus 2 (

236 exchange of information by assuming that all agents share common goals.

237 The emergence of new glucose-lowering agents - sodium-glucose cotransporter 2 inhibitors and i

238 Genotoxic agents such as radiation and chemotherapeutics have been

239 led and slow release of active antimicrobial agents, such as essential oils (EO).

240 Experiments in the presence of an osmoticant agent suggest that channel gating involves a change in s

241 Compared to single-agent sunitinib treatment, tumors in sunitinib-treated E

242 05089771 and suggesting that combinations of agents targeted to the pore-region binding site of lidoc

243 sibility to develop broad-spectrum antiviral agents targeting host factors.

244 BG-P-TAT is a dual-targeting agent, targeting the NET function and the thyrointegrin

245 Direct-acting agents, targeting protease and polymerase functionalitie

246 ic (SWV) detection of the fentanyl and nerve agent targets, respectively.

247 s indicate that, in the presence of crowding agents, tau can undergo liquid-liquid phase separation (

248 ences the sensitivity towards the alkylating agent temozolomide (TMZ).

249 ytotoxicity of treatment with the alkylating agent temozolomide in combination with the PARP inhibito

250 MIC(90) value (4 mg/liter) of any of the 12 agents tested.

251 Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2

252 eleasing molecules (photoCORMs) are chemical agents that allow for precise spatial and temporal contr

253 a large body of preclinical work, promising agents that are entering into early clinical evaluation

254 nstead was induced by membrane-intercalating agents that are prevalent in the host gastrointestinal t

255 c chemotherapies as well as targeted therapy agents that are used to treat breast cancer, pancreatic

256 We propose to identify HIV-1-suppressing agents that can inhibit HIV-1 reactivation and reduce HI

257 uncovered many new paramyxoviruses, airborne agents that cause epidemic diseases in animals including

258 s previous studies on metal-based anticancer agents that cause ER stress.

259 2 and Gcn2 are activated by a similar set of agents that cause ribosome stalling, with maximal activa

260 udy was to develop improved radiotherapeutic agents that combine an optimized affinity-modifying grou

261 lso for the development of new pharmacologic agents that exploit or target TMPRSS6 to treat anemias a

262 apies.Significance: These findings highlight agents that target transcriptional addiction in cancer c

263 treatment (more intensive BP goal or active agent) that involved more than 500 adults with hypertens

264 ns, from biosensors to therapeutic treatment agents, their toxicity and their utility in chemical sen

265 syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependen

266 dence that acalabrutinib is active as single-agent therapy with a manageable safety profile in patien

267 trategy using proteins as structure-directed agents to direct the formation of new ZMOFs that can act

268 for use in humans and can act as anti-cancer agents to inhibit chemotherapy-resistant tumor growth by

269 This care should include bone-targeted agents to inhibit tumour-associated osteolysis and preve

270 urther inform the development of therapeutic agents to modulate pro-inflammatory immune reactions.

271 uch as autologous transfusion techniques and agents to optimize hemostasis are used during surgery an

272 nt recurrence, but could still receive these agents to prevent or treat osteoporosis.

273 se should not be treated with bone-modifying agents to prevent recurrence, but could still receive th

274 he (64)Cu-labeled PSMA ligands are promising agents to target PSMA and visualize PSMA-positive tumor

275 iagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an imp

276 oxicology Paracelsus (1493-1541) on chemical agents used as therapeutics, "the dose makes the poison,

277 y have tradeoffs that depend on the specific agents used as well as their dosing levels and schedule.

278 , solvent, substituent, and type of reducing agent using a synergistic experimental-computational app

279 reflected the agent's beliefs only when the agent was free to act on the ball and not when the agent

280 Global brain redistribution of contrast agent was heterogeneous.

281 1.5 ml/kg of body mass of non-ionic contrast agent was performed.

282 s were indicated, and a guideline-concordant agent was prescribed for guideline-concordant duration)

283 tly demonstrated that bioengineered miR-1291 agent was selectively processed to high levels of target

284 was free to act on the ball and not when the agent was visibly constrained from acting.

285 DDR function and sensitivity to DDR-directed agents, we created a series of ATM-deficient preclinical

286 In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who h

287 in brain, various preblocking or displacing agents were evaluated for their impact on the PET brain

288 a to inhibit angiogenic stimuli to anti-VEGF agents, which inhibit pathologic angiogenesis but also e

289 ot differ when compared with use of the same agent with corticosteroid premedication (P = .10).

290 (CC-122) is a novel oral cereblon-modulating agent with promising activity in non-Hodgkin lymphoma.

291 Cisplatin is a commonly used chemotherapy agent with significant dose-limiting neurotoxicity resul

292 (18)F-flurpiridaz is a novel PET MPI agent with superior image and defect resolution.

293 Epibatidine is a potent analgetic agent with very high affinity for brain nicotinic acetyl

294 provides comparative data on two biological agents with different mechanisms of action, which could

295 ompound is more effective in vivo than other agents with equal tumor uptake due to improved tissue pe

296 We believe that by combining new targeted agents with immune regulators and chimeric antigen recep

297 ch complemented by a hydrodynamic theory for agents with mixed alignment symmetries, which captures t

298 loyed as nonhazardous and greener alkylating agents with the formation of environmentally benign wate

299 utions, which afforded new anti-C. difficile agents with ultrapotent activities [MICs as low as 0.003

300 94B, reversibly bound to native and venomous agent X (VX)-inhibited human AChE, here we created seven